Improper preparation, handling, or sanitation, which may increase the risk of contamination or infection
A large, population-based retrospective cohort study was conducted using the TriNetX platform, which provided real-time access to electronic health records of 634,265 adult patients with MASLD/MASH
The European Medicines Agencys (EMA) Pharmacovigilance Risk Assessment Committee concluded that no product label update was warranted, based on data from clinical trials, real-world safety monitoring, and electronic health records [45]
Updated: 06/15/26 Download Patient SGLT2i HandoutDownload Patient GLP-1 RA Handout These one-page guide will answer your patient's most common questions when starting an SGL2i medication like Jardiance, Farxiga, Invokana, or Steglatro and GLP-1 RA medications like Ozempic, Rybelsus, Trulicity, Victoza, Bydureon BCise, or Byetta
More serious risks include: Pancreatitis Gallbladder issues Risk of thyroid tumors (observed in rodent studies) Patients must weigh these risks carefully, especially when using the medication off-label
159161 Pancreatic polypeptide was also shown to reduce food intake in ob/ob mice and increase energy expenditure
